CD19/22 Bi-specific CAR-T Cell Therapy
NCT05432882
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
B Cell Malignancies
Interventions
BIOLOGICAL:
bi-4SCAR CD19/22 T cells
Sponsor
Shenzhen Geno-Immune Medical Institute